Health Canada Issues Safety Alert for Lupus Drug
OTTAWA, Ontario, Canada — Health Canada, the governmental organization who oversees the safety of medications and medical therapies in Canada, issued an urgent safety warning to people taking the intravenous drug BENLYSTA (belimumab) for SLE or systemic lupus erythematosus (lupus) could experience substantial mental health disorders … [Read more...]
Lupus Medication Can Lead to Depression, Suicide
OTTAWA, Ontario, Canada — On April 4, 2019, Health Canada announced that the lupus drug BENLYSTA (belimumab) might cause depression, suicidal thoughts, or behavior that leads to self-injury. Health Canada warns physicians and patients battling lupus to be wary of any symptoms indicative of depression while taking BENLYSTA (belimumab) … [Read more...]
Health Canada Issues Warning for Benlysta Hypersensitivity and Infusion Reactions
Canadian regulator, Health Canada, has just issued a warning for lupus medication, Benlysta, over hypersensitivity and infusion reactions. Benlysta (belimumab) is a prescription drug approved for the treatment of adults diagnosed with lupus (systemic lupus erythematosus or SLE), who are also being treated with other medications for … [Read more...]
